Julia Rotow, MD

Articles by Julia Rotow, MD

Overview of BRAF V600E–Mutant NSCLC and Rationale for Targeted Therapy

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

November 24th 2025

This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.

Julia Rotow, MD

Articles by Julia Rotow, MD

Overview of BRAF V600E–Mutant NSCLC and Rationale for Targeted Therapy

Latest Updated Articles

Trending on Managed Healthcare Executive

Relmada Therapeutics appoints Max Kates to clinical advisory board to support NDV-01 phase 3 program for bladder cancer

Mechanisms and Clinical Data

MHE Week in Review: Drug-resistant gonorrhea on the rise, masturbation improves menopause symptoms and more

Overview of BRAF V600E–Mutant NSCLC and Rationale for Targeted Therapy

Sarcopenia affects patients with ELD, ILD and pulmonary hypertension, new study shows